Browse studies, page 774

Page 774 of 1,298, newest first. Search them all at once, ranked by relevance, in Evidence Hub.

• Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design The Journal of Headache and Pain, 2017
• A Novel Combination of ω-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study CNS and Neurological Disorders - Drug Targets, 2018
• A Randomized Clinical Trial Comparing the Efficacy of Melatonin and Amitriptyline in Migraine Prophylaxis of Children Iranian journal of child neurology, 2018
• Neck treatment compared to aerobic exercise in migraine: A preference-based clinical trial 2020
• Comparing the Effect of Intranasal Lidocaine 4% with Peppermint Essential Oil Drop 1.5% on Migraine Attacks: A Double-Blind Clinical Trial International Journal of Preventive Medicine, 2019
• Double-blind placebo-controlled randomized clinical trial of ginger (Zingiber officinale Rosc.) in the prophylactic treatment of migraine Cephalalgia, 2019
• Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial 2020
• Anandamide Is Related to Clinical and Cardiorespiratory Benefits of Aerobic Exercise Training in Migraine Patients: A Randomized Controlled Clinical Trial Cannabis and Cannabinoid Research, 2019
• No efficacy of transcranial direct current stimulation on chronic migraine with medication overuse: A double blind, randomised clinical trial Cephalalgia, 2020
• Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial Lancet Neurology, 2024
• Evaluation of Green Light Exposure on Headache Frequency and Quality of Life in Migraine Patients: A Preliminary One-way Cross-over Clinical Trial Cephalalgia, 2020
• Zinc supplementation affects favorably the frequency of migraine attacks: a double-blind randomized placebo-controlled clinical trial Nutrix Journal, 2020
• The efficacy of alpha‐lipoic acid in improving oxidative, inflammatory, and mood status in women with episodic migraine in a randomised, double‐blind, placebo‐controlled clinical trial International journal of clinical practice, 2021
• The effects of nano-curcumin supplementation on Th1/Th17 balance in migraine patients: A randomized controlled clinical trial Complementary Therapies in Clinical Practice, 2020
• Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial Cephalalgia, 2021
• Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial Cephalalgia, 2019
• Enhanced mindfulness based stress reduction (MBSR+) in episodic migraine: a randomized clinical trial with MRI outcomes Pain, 2020
• Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies The Journal of Headache and Pain, 2021
• Effects of Curcumin Supplementation on Clinical Features and Inflammation, in Migraine Patients: A Double-Blind Controlled, Placebo Randomized Clinical Trial International Journal of Preventive Medicine, 2021
• Effectiveness of Mindfulness Meditation vs Headache Education for Adults With Migraine: A Randomized Clinical Trial JAMA Internal Medicine, 2020
• Enhanced mindfulness-based stress reduction (MBSR+) in episodic migraine: effects on sleep quality, anxiety, stress, and depression: a secondary analysis of a randomized clinical trial Pain, 2021
• Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial Journal of the American Medical Association (JAMA), 2021
• The effects of nano-curcumin supplementation on adipokines levels in obese and overweight patients with migraine: a double blind clinical trial study BMC Research Notes, 2022
• Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab The journal of headache and pain, 2025
• Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study Cephalalgia : an international journal of headache, 2024
• Population pharmacokinetics of eptinezumab in paediatric patients with migraine and dose selection for phase 3 paediatric migraine studies Basic & clinical pharmacology & toxicology, 2024
• Cerebrospinal fluid shunting or dural venous sinus stenting to preserve vision in idiopathic intracranial hypertension (IIH Intervention): protocol for an open-label, multicentre, randomised controlled phase IIb trial BMJ open, 2026
• ReVita: home-based transcutaneous auricular vagus nerve stimulation for reducing pathological fatigue in chronic neurological and post-infectious conditions-study protocol for a randomized, double-blind, sham-controlled trial Trials, 2026
• Comparison of Early-onset Efficacy of Anti-calcitonin Gene-related Peptide Monoclonal Antibodies for Patients with Migraine in Real-world Clinical Practice: Study Protocol for an Exploratory Clinical Trial Neurologia medico-chirurgica, 2025
• Single-centre, randomised and double-blind clinical trial on the efficacy of transcutaneous auricular vagus nerve stimulation in preventing and treating primary headache in children and adolescents: a study protocol BMJ open, 2025
• Feasibility and safety profile of intranasal third-party allogeneic CD45RO+/RA- memory T cells: a phase I clinical trial (vRELEASE-I NCT06699758) Frontiers in medicine, 2026
• The influence of renal impairment on the pharmacokinetics of rimegepant: Results of a phase 1, open-label, single-dose, parallel-group study Headache, 2025
• Transcutaneous vagus nerve stimulation as add-on therapy versus pharmacotherapy alone (TRAVAST): study protocol for a prospective, randomised, triple-blind, controlled, multicentre trial BMJ open, 2026
• OnabotulinumtoxinA blockade of the sphenopalatine ganglion in treatment-resistant chronic migraine (MiBlock): rationale, design and study protocol for a multi-centre, investigator initiated, randomised, quadruple-blinded placebo-controlled trial F1000Research, 2025
• Clinical Effectiveness and Cost-Effectiveness of Collaborative Treatment With Korean and Western Medicine for Primary Headache Disorders: Protocol for a Multicenter Prospective Observational Study JMIR research protocols, 2025
• Stage 1 Registered Report: Rationale, design and study protocol for a prospective, exploratory study Predicting Response to image-Guided Cryoneurolysis of the Greater Occipital Nerve (CryoGON) in Chronic Migraine Using a Conventional Greater Occipital Nerve Block F1000Research, 2025
• Differences Among Veterans With Chronic Overlapping Pain Conditions and Other Chronic Pain: Baseline Results From the LAMP Pain Management Trial European journal of pain (London, England), 2025
• Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo-Controlled Study European journal of neurology, 2025
• Evaluating brain mechanisms of combined vagus nerve stimulation and mindfulness training for migraine: A randomized 2 × 2 factorial clinical trial protocol Contemporary clinical trials, 2025
• Physical Therapy Targeting Autonomic and Dura Mater Function: SPINEPASS Randomized Clinical Trial Protocol Physical therapy, 2026
• Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial BMJ open, 2026
• NeuroVision training may improve subjective visual quality in patients with residual refractive error after SMILE: a prospective clinical trial Frontiers in neuroscience, 2026
• Feasibility of a 12-Week, Therapist-Independent, Smartphone-Based Biofeedback Treatment for Episodic Migraine in Adults: Single-Center, Open-Label, 1-Armed Trial JMIR human factors, 2025
• A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose, Double-Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals Clinical pharmacology in drug development, 2026
• Evidence of intrapulmonary penetration of nacubactam, a novel β-lactamase inhibitor, following coadministration of nacubactam with meropenem in healthy adults Antimicrobial agents and chemotherapy, 2026
• Pharmacokinetics and safety of eptinezumab in children and adolescents with migraine Headache, 2025
• Safety, Tolerability, and Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, in Healthy Chinese Participants Clinical pharmacology in drug development, 2025
• Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial The Lancet. Neurology, 2025
• Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine Cephalalgia : an international journal of headache, 2025
• The comparative effectiveness of progressive relaxation training on pain characteristics, attack frequency, activity self-efficacy, and pain-related disability in women with episodic tension-type headache and migraine PloS one, 2025
• Myofascial trigger points therapy increases neck mobility and reduces headache pain in migraine patients - pilot study BMC musculoskeletal disorders, 2025
• Protocol for a randomized controlled trial evaluating a digital behavioral self-management intervention for adolescent migraine Applied nursing research : ANR, 2025
• Protocol for BASE: a multicentre, double-blind, randomised, controlled trial of bupropion hydrochloride in acute ischaemic stroke in China BMJ open, 2026
• A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine Headache, 2026
• A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine Headache, 2026
• Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study The journal of headache and pain, 2025
• Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose-ranging, double-blind, randomized controlled trial Headache, 2025
• Efficacy and safety of mAbs anti-CGRP/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol Pain management, 2025
• Rimegepant safety and patient-reported outcomes among triptan-naïve, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study Cephalalgia : an international journal of headache, 2025
• Long-term safety and tolerability of zavegepant 10-mg nasal spray with concomitant use of anti-calcitonin gene-related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open-label study Headache, 2025
• Scalp cooling versus standard cold-cap in preventing chemotherapy-induced alopecia in patients with localized breast cancer: ICELAND protocol, a randomized controlled trial and economic evaluation PloS one, 2026
• OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial Cephalalgia : an international journal of headache, 2025
• Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial Cephalalgia : an international journal of headache, 2025
• Ultrasound-Guided Stellate Ganglion Block for the Treatment of Chronic Migraine in Adults: Study Protocol for a Randomized, Open-Label, Blinded Endpoint Trial Pain physician, 2025
• A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Intranasal Dose of Zavegepant in Healthy Chinese Adults Clinical pharmacology in drug development, 2026
• Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China Cephalalgia : an international journal of headache, 2025
• Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial The Lancet. Neurology, 2025
• Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial Cephalalgia : an international journal of headache, 2025
• Does C1 esterase inhibitor play a role in post COVID-19 neurological symptoms? A randomized, double-blind, placebo-controlled, crossover, proof-of-concept study Frontiers in neurology, 2025
• Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine Cephalalgia : an international journal of headache, 2025
• Long-term real-world effectiveness and safety of fremanezumab in 1140 patients with migraine and at least 6 months of treatment: third interim analysis of the pan-European PEARL study Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025
• Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial PloS one, 2026
• The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectiveness Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025
• A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women Headache, 2026
• Pragmatic open-label clinical trial investigating the treatment effects of Ginkgo biloba extract EGb 761 on patients with vertigo and dizziness of various aetiologies Frontiers in pharmacology, 2026
• OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open-Label (COMPEL) trial Headache, 2026
• Soluble guanylate cyclase induces cranial vasodilation and headache in adults: a randomized trial Brain communications, 2025
• Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE) Cephalalgia : an international journal of headache, 2025
• Comparison of the effectiveness of first-line preventive treatment of migraine in primary care: study protocol for a pragmatic clinical trial (PREMI study) Trials, 2025
• Association of nociceptive, neurocognitive, psychological and genetic profile on conditioned pain modulation in women with migraine: protocol for a case-control study BMJ open, 2025
• Addressing unmet needs in migraine: Real-world fremanezumab effectiveness in participants of the PEARL study with at least three prior preventive treatment failures Cephalalgia : an international journal of headache, 2025
• Relationship Between Central Sensitization and Genetic Polymorphisms-A Case-Control Study in Fibromyalgia European journal of pain (London, England), 2026
• Clinical Efficacy and Plasma Metabolomics Analysis of Acupuncture for Migraine Treatment Journal of pain research, 2025
• Population Pharmacokinetics of Atogepant for the Prevention of Migraine Clinical pharmacokinetics, 2026
• Auricular neuromodulation by low level laser therapy versus placebo laser therapy in prophylactic treatment of episodic migraine: a randomized controlled study protocol BMC complementary medicine and therapies, 2025
• Higher Circulating IL-6 levels as a predictor for poor outcome after migraine preventive treatment: a prospective study The journal of headache and pain, 2025
• Effect of mixodin supplementation on inflammatory and oxidative stress markers, clinical symptoms, mental health, and quality of life in patients with migraine: study protocol for a randomized clinical trial Trials, 2025
• A randomised, participant- and assessor-blinded, sham-controlled trial investigating acupuncture for disorders of gut-brain interaction in children (P-GAP) BMJ open, 2026
• A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention The journal of headache and pain, 2025
• Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open-Label Trial Clinical and translational science, 2026
• Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study Cephalalgia : an international journal of headache, 2026
• Development of a Standardised stroke risk assessment for patients with MigraAinous symptoms Reviewed as suspected TIA (SMART): study protocol for a mixed methods study BMJ open, 2025
• Protocol for a randomised, double-blind, placebo-controlled clinical trial on the effects of high-dose vitamin B multivitamin supplementation with and without Passiflora incarnata on neural connectivity and oxidative metabolism in healthy adults BMJ open, 2026
• Electroacupuncture for Menstrual-Related Migraine: Protocol for a Multicenter Single-Blinded Randomized Controlled Trial Pain research & management, 2026
• Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans Clinical and translational science, 2026
• Food-specific IgG-based elimination diet decreased IL-6, TNF-α, and CGRP and improved symptoms in adults with migraine Frontiers in nutrition, 2025
• Effects of erenumab on migraine aura frequency: a REFORM study The journal of headache and pain, 2026
• Prospective open-label trial of personalised connectivity-guided transcranial magnetic stimulation therapy for migraine The journal of headache and pain, 2026
• Therapeutic efficacy of nimodipine and topiramate on migraine and vestibular migraine; A prospective multicenter open-label study PloS one, 2026
• An Open-Label, 2-Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects Journal of clinical pharmacology, 2026